Skip to main content
. 2013 Feb 4;55(9):2151–2160. doi: 10.3109/10428194.2013.856008

Figure 4.

Figure 4.

Kaplan–Meier curves for time-to-event until day 43 in s.c. implanted Z138 MCL xenografts treated with obinutuzumab (GA101) monotherapy, obinutuzumab (GA101)/fludarabine combination therapy, and rituximab plus fludarabine combination therapy.